Pharmacovigilance of the Covid19 therapeutic protocol: Experience of the Hassan II University Hospital of Fez, Morocco and analysis of national and international data

Faced with the pandemic related to the dissemination of the new Coronavirus and the health emergency, Morocco decided to treat patients with Covid-19 with Hydroxychloroquine (HCQ) or Chloroquine (CQ), associated with Azithromycin (AZM) according to a standardized therapeutic scheme, an off-label ind...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hoummani Hasnae, Mourabiti Hajar, Chebaibi mohamed, Achour Sanae
Formato:	article
Lenguaje:	EN FR
Publicado:	EDP Sciences 2021
Materias:	Environmental sciences GE1-350
Acceso en línea:	https://doaj.org/article/a0f9fc53f972486f91dec7555b6a27a0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a0f9fc53f972486f91dec7555b6a27a0
record_format	dspace
spelling	oai:doaj.org-article:a0f9fc53f972486f91dec7555b6a27a02021-11-12T11:44:08ZPharmacovigilance of the Covid19 therapeutic protocol: Experience of the Hassan II University Hospital of Fez, Morocco and analysis of national and international data2267-124210.1051/e3sconf/202131901025https://doaj.org/article/a0f9fc53f972486f91dec7555b6a27a02021-01-01T00:00:00Zhttps://www.e3s-conferences.org/articles/e3sconf/pdf/2021/95/e3sconf_vigisan_01025.pdfhttps://doaj.org/toc/2267-1242Faced with the pandemic related to the dissemination of the new Coronavirus and the health emergency, Morocco decided to treat patients with Covid-19 with Hydroxychloroquine (HCQ) or Chloroquine (CQ), associated with Azithromycin (AZM) according to a standardized therapeutic scheme, an off-label indication that required pharmacovigilance monitoring to ensure the safety of treated patients. Objective. To present the experience of the Hassan II University Hospital of Fez concerning the management of adverse events of the Covid19 therapeutic protocol. A notification form was made available to the nursing staff to be filled in for any adverse reaction (ADR) observed after the treatment was taken. A daily collection and in-depth analysis was performed. We present the results of the analysis of the data collected in our training between April 21 and August 22, 2020, discussing them with data from national and international databases. 102 ADR cases were collected out of 915 patients hospitalized at the UHC for Covid19 during this period with a prevalence of 11%. 23 patients had underlying defects. The incriminating protocol contained CQ in 55.8% and HCQ in 44.2%. The mean age of the patients was 40.83±17.1 years (18 to 86 years) with a M/F sex ratio of 0.92. The mean time to onset was 3 days (range 1-6 days). The most noted ADRs were digestive, cardiac and neurological. 14 cases were severe (one QT prolongation), 6 of which required transfer to an intensive care unit. The course of action adopted was the restoration of corrective treatment with 12 cases of treatment discontinuation and 8 cases of switching to 2nd line treatment.Hoummani HasnaeMourabiti HajarChebaibi mohamedAchour SanaeEDP SciencesarticleEnvironmental sciencesGE1-350ENFRE3S Web of Conferences, Vol 319, p 01025 (2021)
institution	DOAJ
collection	DOAJ
language	EN FR
topic	Environmental sciences GE1-350
spellingShingle	Environmental sciences GE1-350 Hoummani Hasnae Mourabiti Hajar Chebaibi mohamed Achour Sanae Pharmacovigilance of the Covid19 therapeutic protocol: Experience of the Hassan II University Hospital of Fez, Morocco and analysis of national and international data
description	Faced with the pandemic related to the dissemination of the new Coronavirus and the health emergency, Morocco decided to treat patients with Covid-19 with Hydroxychloroquine (HCQ) or Chloroquine (CQ), associated with Azithromycin (AZM) according to a standardized therapeutic scheme, an off-label indication that required pharmacovigilance monitoring to ensure the safety of treated patients. Objective. To present the experience of the Hassan II University Hospital of Fez concerning the management of adverse events of the Covid19 therapeutic protocol. A notification form was made available to the nursing staff to be filled in for any adverse reaction (ADR) observed after the treatment was taken. A daily collection and in-depth analysis was performed. We present the results of the analysis of the data collected in our training between April 21 and August 22, 2020, discussing them with data from national and international databases. 102 ADR cases were collected out of 915 patients hospitalized at the UHC for Covid19 during this period with a prevalence of 11%. 23 patients had underlying defects. The incriminating protocol contained CQ in 55.8% and HCQ in 44.2%. The mean age of the patients was 40.83±17.1 years (18 to 86 years) with a M/F sex ratio of 0.92. The mean time to onset was 3 days (range 1-6 days). The most noted ADRs were digestive, cardiac and neurological. 14 cases were severe (one QT prolongation), 6 of which required transfer to an intensive care unit. The course of action adopted was the restoration of corrective treatment with 12 cases of treatment discontinuation and 8 cases of switching to 2nd line treatment.
format	article
author	Hoummani Hasnae Mourabiti Hajar Chebaibi mohamed Achour Sanae
author_facet	Hoummani Hasnae Mourabiti Hajar Chebaibi mohamed Achour Sanae
author_sort	Hoummani Hasnae
title	Pharmacovigilance of the Covid19 therapeutic protocol: Experience of the Hassan II University Hospital of Fez, Morocco and analysis of national and international data
title_short	Pharmacovigilance of the Covid19 therapeutic protocol: Experience of the Hassan II University Hospital of Fez, Morocco and analysis of national and international data
title_full	Pharmacovigilance of the Covid19 therapeutic protocol: Experience of the Hassan II University Hospital of Fez, Morocco and analysis of national and international data
title_fullStr	Pharmacovigilance of the Covid19 therapeutic protocol: Experience of the Hassan II University Hospital of Fez, Morocco and analysis of national and international data
title_full_unstemmed	Pharmacovigilance of the Covid19 therapeutic protocol: Experience of the Hassan II University Hospital of Fez, Morocco and analysis of national and international data
title_sort	pharmacovigilance of the covid19 therapeutic protocol: experience of the hassan ii university hospital of fez, morocco and analysis of national and international data
publisher	EDP Sciences
publishDate	2021
url	https://doaj.org/article/a0f9fc53f972486f91dec7555b6a27a0
work_keys_str_mv	AT hoummanihasnae pharmacovigilanceofthecovid19therapeuticprotocolexperienceofthehassaniiuniversityhospitaloffezmoroccoandanalysisofnationalandinternationaldata AT mourabitihajar pharmacovigilanceofthecovid19therapeuticprotocolexperienceofthehassaniiuniversityhospitaloffezmoroccoandanalysisofnationalandinternationaldata AT chebaibimohamed pharmacovigilanceofthecovid19therapeuticprotocolexperienceofthehassaniiuniversityhospitaloffezmoroccoandanalysisofnationalandinternationaldata AT achoursanae pharmacovigilanceofthecovid19therapeuticprotocolexperienceofthehassaniiuniversityhospitaloffezmoroccoandanalysisofnationalandinternationaldata
_version_	1718430635039653888

Pharmacovigilance of the Covid19 therapeutic protocol: Experience of the Hassan II University Hospital of Fez, Morocco and analysis of national and international data

Ejemplares similares